Pharmacodynamics of Antimicrobials William A. Craig, M.D. University of Wisconsin-Madison.

Slides:

Advertisements

Similar presentations

Intravenous Antibiotics in the Community

Advertisements

Is Vancomycin Obsolete for Treating Serious Staphylococcal Infections? Part I Edward L. Goodman, MD, FACP, FIDSA, FSHEA August 26, 2009.

Antibiotic use in critical care

Pharmacodynamics of MASKO Compounds (Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones) William A. Craig, MD University of Wisconsin.

Animal Model PK/PD: A Tool for Drug Development

Choosing Antimicrobials in Special Situations. Additional considerations in making a final antibiotic selection Site of action – (Will the antibiotic.

Introduction to Antimicrobial Therapy

Pharmacodynamics and the Dosing of Antibacterials

Inhibitory and bactericidal concentrations of current and new antibiotics for Methicillin-resistant Staphylococcal ocular infections Yousuf Qureshi, M.D.

The ABC’s of Antibiotics

Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint ® Lecture Slide Presentation prepared by Christine L. Case Microbiology.

Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.

Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.

Pharmacodynamics of Antibiotics

The (important) role of the pharmacist in the handling of COPD - H. Lode - Free University Berlin.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

WHICH PK-PD MEASURE FOR WHICH DRUG? Sujata M. Bhavnani, Pharm.D, MS Institute for Clinical Pharmacodynamics Ordway Research Institute Latham, New York.

Antimicrobial compounds Antiseptics and disinfectants Antibiotics.

Sub-MIC effects in vitro and in vivo Inga Odenholt, MD., Ph.D. Department of Infectious Diseases University hospital Malmö Sweden.

S. Balakrishnan Department of Pharmacology, Pondicherry Institute of Medical Sciences.

Rational use of antibiotics in child infection

Effect of Adequate Antimicrobial Therapy For Bloodstream Infections on Mortality

PK/PD Dosing in Critical Care Jim Fenner Pharm D BCPS.

Ch 20: Antimicrobial Drugs ChemotherapyThe use of drugs to treat a disease Antimicrobial drugsInterfere with the growth of microbes within a host AntibioticSubstance.

8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

The War on Drugs: The Mythology of Antibiotics Edward L. Goodman, MD, FACP, FIDSA, FSHEA May 9, 2005.

PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.

Antimicrobial Drugs.

Can and Should ß-lactams be Given by Continuous Infusion? John Turnidge Women’s & Children’s Hospital Adelaide 24 th ICC Manila / ISAP symposium.

Preclinical Models to Support Dosage Selection

Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.

Ten Years After: Where is ISAP?

Michael R. Jacobs, MD, PhD FDA Presentation Nov 7, 2001

Pharmacodynamics of Antifungals

The Rational Use of Antibiotics

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

In Vitro models of Infections: the postantibiotic and sub-MIC effects in vitro and in vivo Inga Odenholt, MD., Ph.D. Department of Infectious Diseases.

PK/PD for antibiotics: an overview

Where can we wrong; while prescribing right dose of antibiotics

Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.

PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,

JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.

Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,

Agents for the Treatment of MRSA: Pharmakokinetics &Pharmacodynamics

By: Alaina Darby Intro to Antibiotics.  Intro to Antimicrobials Overview  Practice Questions  Specific Things to Remember  Helpful Tips for the Test.

Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings PowerPoint ® Lecture Slide Presentation prepared by Christine L. Case M I C R.

MACROLIDES: pharmacokinetics and pharmacodynamics

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

International Society for Anti-infective Pharmacology (ISAP)

International Society for Anti-infective Pharmacology (ISAP)

Unité de Pharmacologie Cellulaire et Moléculaire

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.

Unité de Pharmacologie Cellulaire et Moléculaire

Intro to Antibiotics By: Alaina Darby.

PK/PD: from theory to applications in the real world...

General considerations of antimicrobial agents (抗微生物药物概论)

Optimizing Aminoglycoside Use

Overview of Antimicrobials

PK/PD: an introduction with the case of antimicrobials

Thomas P. Lodise, PharmD, G.L. Drusano, MD Critical Care Clinics

Pharmacodynamic indices in targeting therapy of critical infections

Chemotherapeutic Medicine

Department of Emergency Medicine Yonsei University Health System

M.R. Jacobs Clinical Microbiology and Infection

Dose optimization as an antimicrobial stewardship strategy

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

Antibiotics Drug Classes Revisiting Basic Principles

Introduction to Antibiotics

Presentation transcript:

Pharmacodynamics of Antimicrobials William A. Craig, M.D. University of Wisconsin-Madison

Potency: 1. MIC 2. MBC Time Course of Activity: 1. Rate of killing and effect of increasing concentrations 2. Persistent effects (PAE, PA-SME, and PALE) Parameters of Antimicrobial Activity

Patterns of Antimicrobial Activity  Concentration-dependent killing and prolonged persistent effects  Seen with aminoglycosides, fluoroquinolones, daptomycin and amphotericin B  Goal of dosing regimen: maximize concentrations; once-daily dosing  AUC/MIC and Peak/MIC major parameters correlating with efficacy

Patterns of Antimicrobial Activity  Time-dependent killing and minimal to moderate persistent effects  Seen with penicillins, cephalosporins, aztreonam, carbapenems, tribactams, clindamycin, macrolides, and oxazolidinones  Goal of dosing regimen: optimize duration of exposure; continuous infusion  Time above MIC (T>MIC) is major parameter correlating with efficacy

Patterns of Antimicrobial Activity  Time-dependent killing and prolonged persistent effects (duration related to AUC)  Seen with glycopeptides, tetracyclines, azithromycin, ketolides, streptogramins, glycylcyclines, everninomicins, and fluconazole  Goal of dosing regimen: optimize amount of drug  AUC/MIC major parameter correlating with efficacy